Skip to main content

Table 1 Baseline characteristics of the study population

From: A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria

Demographic Ergocalciferol plus placebo (n = 36) Ergocalciferol plus calcitriol (n = 32) P-value
Age (years) 62.56 ± 12.91 63.13 ± 11.29 0.85
Male sex (%) 15 (41.67) 17 (53.13) 0.35
Cause of CDK
− Diabetic nephropathy 19 (52.78) 20 (62.5) 0.43
− Chronic glomerulonephritis 4 (11.11) 4 (12.5) 0.88
− IgA nephropathy 1 (2.78) 2 (6.25) 0.48
− Focal segmental glomerulosclerosis 3 (8.33) 1 (3.13) 0.35
− Polycystic kidney disease 1 (11.11) 0 (0) 0.31
− Unknown 8 (22.22) 5 (15.63) 0.49
Blood pressure (mmHg)
− Systolic 136.69 ± 14.56 137.75 ± 14.78 0.77
− Diastolic 75.75 ± 10.46 77.13 ± 11.68 0.61
Serum creatinine (mg/dL) 2.19 ± 0.9 2.43 ± 0.9 0.29
eGFR (ml/min/1.73 m2) 39.29 ± 11.26 37.29 ± 11.44 0.47
Serum cystatin C (mg/L) 2.07 ± 0.61 2.13 ± 0.67 0.70
25-hydroxy vitamin D level (ng/ml) 15.89 ± 6.59 19.26 ± 5.12 0.02
Urine protein to creatinine ratio (g/g)
− mean ± SD 3.47 ± 3.01 3.61 ± 3.75 0.87
Serum calcium (mg/dl) 9.4 ± 0.49 9.27 ± 0.47 0.27
Serum phosphorus (mg/dl) 3.58 ± 0.58 3.8 ± 0.78 0.17
Serum albumin (g/dl) 3.83 ± 0.42 3.95 ± 0.34 0.21
Serum intact parathyroid hormone (pg/mL) 85.11 ± 47.42 88.57 ± 64.49 0.60
Serum HbA1C (%) 7.17 ± 0.78 7.40 ± 0.59 0.31
Antihypertensive drug (%)
− ARB 8 (22.22) 11 (34.38) 0.27
− ACE inhibitor 10 (27.78) 8 (25) 0.79